Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (GB:0UJF)
LSE:0UJF
RESEARCH TOOLSreports
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.2Last Year’s EPS
0.01Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 0.00%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong quarter with significant revenue growth, improved cash flow, and reduced operating expenses. However, there are ongoing challenges, including patent litigation, potential regulatory risks, and competition in the lupus nephritis treatment market.Company Guidance
During the Aurinia Pharmaceuticals Inc. Q1 2025 Earnings Call, the company provided guidance for the fiscal year, projecting total revenue in the range of $250 million to $260 million and net product sales of LUPKYNIS between $240 million and $250 million. The call highlighted a strong performance in the first quarter, with total revenue reaching $62.5 million, a 24% increase from $50.3 million in Q1 2024, and net product sales of LUPKYNIS at $60 million, up 25% from $48.1 million in the previous year. The company also reported a notable improvement in cash flow, generating $1.3 million from operations, compared to a negative cash flow of $18.6 million in Q1 2024. Aurinia ended the quarter with cash, cash equivalents, restricted cash, and investments totaling $312.9 million. The company remains focused on commercial execution and operational efficiency, aiming to capitalize on the updated American College of Rheumatology lupus nephritis treatment guidelines by promoting LUPKYNIS as a first-line therapy. Additionally, Aurinia is on track to report initial Phase 1 results for AUR200 later in the quarter.Strong Revenue Growth
Total revenue for Q1 2025 was $62.5 million, up 24% from $50.3 million in Q1 2024. Net product sales of LUPKYNIS were $60 million, up 25% from $48.1 million in the same period of 2024.
Improved Cash Flow
Cash flow generated from operations was $1.3 million in Q1 2025, compared to a negative $18.6 million in Q1 2024. Excluding restructuring payments, cash flow was $12.4 million.
Positive Net Income
Net income for Q1 2025 was $23.3 million or $0.17 per share, compared to a net loss of $10.7 million or $0.07 per share in Q1 2024.
Efficient Operations
Total operating expenses decreased to $40.6 million in Q1 2025 from $63.6 million in Q1 2024, primarily due to strategic restructuring efforts.
Rheumatology Market Growth
The company is focusing on educating rheumatologists about LUPKYNIS, seeing improvements in rheumatology prescribing.
Pipeline Progress
The company remains on track to report initial results from the Phase 1 study of AUR200, a dual BAFF/APRIL inhibitor, later in the quarter.
---
GB:0UJF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0UJF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | C$15.41 | C$15.41 | 0.00% |
Feb 27, 2025 | C$15.41 | C$15.41 | 0.00% |
Nov 07, 2024 | C$15.41 | C$15.41 | 0.00% |
Aug 01, 2024 | C$15.41 | C$15.41 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aurinia Pharmaceuticals (GB:0UJF) report earnings?
Aurinia Pharmaceuticals (GB:0UJF) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Aurinia Pharmaceuticals (GB:0UJF) earnings time?
Aurinia Pharmaceuticals (GB:0UJF) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Aurinia Pharmaceuticals stock?
The P/E ratio of Aurinia Pharmaceuticals is N/A.
What is GB:0UJF EPS forecast?
GB:0UJF EPS forecast for the fiscal quarter 2025 (Q2) is 0.2.
---
